Wagstaff, J., James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., . . . Parmar, M. K. B. (2015). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet. doi:10.1016/S0140-6736(15)01037-5
Chicago Style CitationWagstaff, John, et al. "Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results From an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial." The Lancet 2015.
MLA CitationWagstaff, John, et al. "Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results From an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial." The Lancet 2015.